The work by Le Boeuf et al. demonstrated that vaccinia virus can alleviate innate immune barriers and enhance VSV-mediated tumor killing through the secretion of B18R, a soluble interferon (IFN) decoy receptor that sequesters type I IFNs and prevents them from activating antiviral signaling [79]. The gene discussed is IFNA1; the disease is neoplasm.